A Phase 1, Open-Label, Dose-Ranging, Safety and Pharmacokinetic Study to Determine the Maximum Tolerated Dose of RX-3117 Administered Orally as a Single-Agent to Subjects With Advanced Malignancies

Trial Profile

A Phase 1, Open-Label, Dose-Ranging, Safety and Pharmacokinetic Study to Determine the Maximum Tolerated Dose of RX-3117 Administered Orally as a Single-Agent to Subjects With Advanced Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Fluorocyclopentenylcytosine (Primary)
  • Indications Bladder cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Rexahn Pharmaceuticals
  • Most Recent Events

    • 12 Sep 2017 Results (dat cut-off date: May 2017, n=10) from stage-1 of phase 2a clinical study of RX-3117 as a single agent in subjects with advanced urothelial cancer, presented at the 42nd European Society for Medical Oncology Congress.
    • 11 Sep 2017 According to a Rexahn Pharmaceuticals media release, completion of the phase 2a study and reporting additional data is expected over the coming months.
    • 10 Sep 2017 Results from phase 2a published in a Rexahn Pharmaceuticals Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top